Back to mobile site

Teva Pharma (TEVA): Downside From $16 Likely, Cutting PT - Cowen

October 4, 2017 9:28 AM EDT Send to a Friend
Cowen analyst, Ken Cacciatore, reiterated his Market Perform rating on shares of Teva Pharma (NYSE: TEVA) and cut his price ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login